5-Amino-1MQ vs Tesofensine
A side-by-side research comparison of 5-Amino-1MQ and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-Amino-1MQ | Tesofensine |
|---|---|---|
| Full name | 5-Amino-1-Methylquinolinium (NNMT Inhibitor) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Inhibits NNMT enzyme, preventing methylation and degradation of nicotinamide. Increases intracellular NAD+ pools, activates sirtuins, and reduces fat cell size without affecting food intake. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 173.2 Da | 329.4 Da |
| Half-life | 8-12 hours | 8-10 days |
| Bioavailability | High (oral) | High (oral ~93%) |
| Typical dose | 50-100 mg | 0.25-0.5 mg |
| Frequency | 1-2x daily | Once daily |
| Route | Oral (capsule) | Oral |
5-Amino-1MQ reported benefits
- Increased cellular energy metabolism
- Reduced fat cell size
- Elevated NAD+ levels
- Does not suppress appetite
- Improved muscle stem cell function
- Oral convenience
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.